Rivastigmine

Excerpt

An 81-year-old man, who had Alzheimer disease, presented with hypersexuality. He started transdermal rivastigmine, starting with a daily dose of 4.6mg. After 1 month, his sexual behaviour disorder improved, and rivastigmine was increased to 9.5 mg/day. After 4 months of treatment, he spontaneously discontinued rivastigmine due to the occurrence of erythematous and itchy lesions on the skin areas of the transdermal systems application. Subsequently, his sexual behaviour worsened, and oral rivastigmine was gradually restarted. His sexual behaviour improved; at a 3-year follow-up, the beneficial effects of rivastigmine were still present [outcome of skin lesions not stated]. …